The abstract is read at the publisher; the summary is JClub's.
AI evidence across vaccine clinical trial lifecycles is strongest for operational uses—especially recruitment, eligibility screening, trial matching, and risk-based monitoring—while immune interpretation and safety surveillance are less prospectively validated.
- Why it matters: Vaccine trials face high safety expectations in healthy participants, shifting exposure and baseline immunity, incomplete correlates of protection, and public scrutiny, creating a need for evidence-based AI adoption.
- What they did: The authors performed a structured vaccine-focused narrative review of AI applications across the trial lifecycle, supplemented by targeted clinical trial and vaccine pharmacovigilance studies using directly transferable methods.
- The result: The combined evidence base suggests operational AI is most ready, whereas tools for immune-response interpretation, correlates of protection, and vaccine safety surveillance are promising but not yet as prospectively validated, informing guardrails for responsible use.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.